» Articles » PMID: 23172308

1p36 Tumor Suppression--a Matter of Dosage?

Overview
Journal Cancer Res
Specialty Oncology
Date 2012 Nov 23
PMID 23172308
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

A broad range of human malignancies is associated with nonrandom 1p36 deletions, suggesting the existence of tumor suppressors encoded in this region. Evidence for tumor-specific inactivation of 1p36 genes in the classic "two-hit" manner is scarce; however, many tumor suppressors do not require complete inactivation but contribute to tumorigenesis by partial impairment. We discuss recent data derived from both human tumors and functional cancer models indicating that the 1p36 genes CHD5, CAMTA1, KIF1B, CASZ1, and miR-34a contribute to cancer development when reduced in dosage by genomic copy number loss or other mechanisms. We explore potential interactions among these candidates and propose a model where heterozygous 1p36 deletion impairs oncosuppressive pathways via simultaneous downregulation of several dosage-dependent tumor suppressor genes.

Citing Articles

Diagnostic challenges in complicated case of glioblastoma.

Aghova T, Lhotska H, Lizcova L, Svobodova K, Hodanova L, Janeckova K Pathol Oncol Res. 2024; 30:1611875.

PMID: 39534304 PMC: 11554483. DOI: 10.3389/pore.2024.1611875.


Case Report: Aggressive neural crest tumors in a child with familial von Hippel Lindau syndrome associated with a germline mutation (c.414A>G) and a novel gene mutation.

Landen L, De Leener A, Le Roux M, Brichard B, Aydin S, Maiter D Front Endocrinol (Lausanne). 2023; 14:1204793.

PMID: 37564981 PMC: 10411570. DOI: 10.3389/fendo.2023.1204793.


A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy.

Li L, Shu X, Geng H, Ying J, Guo L, Luo J Cell Death Differ. 2023; 30(5):1166-1183.

PMID: 36813924 PMC: 10154315. DOI: 10.1038/s41418-023-01129-w.


In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.

Wirth A, Wange L, Vosberg S, Henrich K, Rausch C, Ozdemir E Leukemia. 2022; 36(12):2863-2874.

PMID: 36333584 PMC: 9712105. DOI: 10.1038/s41375-022-01726-7.


Transcription factor CASZ1 increases an oncogenic transcriptional process in tumorigenesis and progression of glioma cells.

Mao C, Huang C, Hu Z, Qu S MedComm (2020). 2022; 3(4):e182.

PMID: 36276925 PMC: 9583698. DOI: 10.1002/mco2.182.